Skip to content
10-Q

Quarterly Report

Atara Biotherapeutics, Inc. ATRA

0001193125-26-219482

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 9.01M sh
Shares Diluted Q1 2026 · Mar 31, 2026 14.08M sh
Shares Diluted Q1 2026 · Mar 31, 2025 10.85M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.07M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$28.14M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $8.36M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $8.48M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$37.31M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$38.5M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$55.07M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$97.28M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.65M
Current Liabilities Q1 2026 · Dec 31, 2025 $14.92M
Total Liabilities Q1 2026 · Mar 31, 2026 $57.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $58.74M
Current Assets Q1 2026 · Mar 31, 2026 $12.17M
Current Assets Q1 2026 · Dec 31, 2025 $12.21M
Total Assets Q1 2026 · Mar 31, 2026 $20M
Total Assets Q1 2026 · Dec 31, 2025 $20.24M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.29
Eps Diluted Q1 2026 · Mar 31, 2025 $3.50
Eps Basic Q1 2026 · Mar 31, 2026 −$0.29
Eps Basic Q1 2026 · Mar 31, 2025 $3.53
Sga Expense Q1 2026 · Mar 31, 2026 $3.6M
Sga Expense Q1 2026 · Mar 31, 2025 $11.48M
Rd Expense Q1 2026 · Mar 31, 2026 $164K
Rd Expense Q1 2026 · Mar 31, 2025 $27.43M
Net Income Q1 2026 · Mar 31, 2026 −$4.15M
Net Income Q1 2026 · Mar 31, 2025 $38.01M
Operating Income Q1 2026 · Mar 31, 2026 −$3.37M
Operating Income Q1 2026 · Mar 31, 2025 $38.8M
Revenue Q1 2026 · Mar 31, 2026 $516K
Revenue Q1 2026 · Mar 31, 2025 $98.15M